
A new drug called veligrotug has shown promising results in reducing proptosis (eye bulging) and other vision issues for people with thyroid eye disease (TED). In a recent phase 3 clinical trial, 70 percent of those treated with veligrotug had improvement in eye bulging, compared to only 5 percent of those given a placebo (inactive treatment). For over half of the participants, the study treatment also helped relieve diplopia (double vision), a symptom often linked to the eye swelling and pressure of TED. Additionally, 64 percent of participants achieved little to no eye inflammation, which reduces pain, redness, and eyelid swelling.
Veligrotug works by blocking insulin-like growth factor 1 receptor (IGF-1R), a protein involved in the immune response that causes tissue to swell around the eyes in TED. It’s similar to teprotumumab (Tepezza), the first medication approved by the U.S. Food and Drug Administration (FDA) to treat moderate to severe TED. Teprotumumab also targets IGF-1R. By stopping this protein, veligrotug helps reduce pressure, swelling, and symptoms like bulging eyes and double vision. Further clinical trials are underway.
Eye bulging, double vision, and inflammation around the eyes are challenging TED symptoms. These are typically managed with steroids, teprotumumab, lubricating eye drops, radiation therapy, and sometimes surgery in severe cases. Double vision may also be treated with prism glasses or eye muscle surgery. The IGF-1R-targeted infusion approach may reduce the need for invasive procedures and offer faster, more comprehensive symptom control. If you’re living with TED and experiencing eye bulging, double vision, or eye discomfort, speak with your health care provider about treatment options.
Learn more about IGF-1R-targeting drugs and 10 other treatment options for TED.
On TEDhealthteam, the social network for people living with thyroid eye disease and their loved ones, members come together to ask questions, give advice, and share their stories with others who understand life with TED.
Have you noticed changes in your eyes from TED? How do you manage symptoms? Share your tips and experiences in a comment below, or start a conversation on your Activities page.
Ted Samson
is a content innovation editor at MyHealthTeam.
Learn more about him here.
Get updates directly to your inbox.
Continue with Facebook
Sign up with your email
Become a member to get even more
A TEDhealthteam Member
I would like to participate in a study for individuals whose had TED for 5 years. Every medication study that I've seen was for new onset TED (1 year or less).
We'd love to hear from you! Please share your name and email to post and read comments.
You'll also get the latest articles directly to your inbox.